PT. JES Kasih Nusantara Sejahterah

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

Dendritic cell immunotherapy · Oncology
Dendritic cell immunotherapy activates the patient's own dendritic cells to present tumor antigens and stimulate a cytotoxic T-cell response against cancer cells.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

PT. JES Kasih Nusantara Sejahterah portfolio CI brief
PT. JES Kasih Nusantara Sejahterah pipeline updates RSS